-
Signature
-
/s/ Will Solis, Attorney-in-Fact
-
Stock symbol
-
BBIO
-
Transactions as of
-
Oct 27, 2025
-
Transactions value $
-
-$106,665
-
Form type
-
4
-
Date filed
-
10/29/2025, 05:10 PM
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| MCCORMICK FRANK |
Director |
C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO |
/s/ Will Solis, Attorney-in-Fact |
2025-10-29 |
0001257809 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
BBIO |
Common Stock |
Sale |
-$107K |
-1.64K |
-0.19% |
$65.00 |
878K |
Oct 27, 2025 |
By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017 |
F1 |
| holding |
BBIO |
Common Stock |
|
|
|
|
|
83.3K |
Oct 27, 2025 |
Direct |
|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: